Travere TherapeuticsTVTX
Recorded

Travere Therapeutics 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 0 minParticipants18

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon, and welcome to the Travere Therapeutics Third Quarter 2026 Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the conference call over to Ryan Hayes, Investor Relations Analyst. Please go ahead, Ryan. Thank you, operator.

Ryan HayesInvestor Relations Analyst

Good afternoon, and welcome to Travere Therapeutics' Third Quarter 2026 Financial Results and Corporate Update Call. Thank you all for joining. Today's call will be led by Dr. Eric Dube, our President and Chief Executive Officer. Eric will be joined in the prepared remarks by Peter Heerma, our Chief Commercial Officer, Dr. Jula Inrig, our Head of R&D and Chief Medical Officer, and Chris Cline, our Chief Financial Officer. Dr. Bill Rote, our Chief Research Officer, will join us for the Q&A. Before we begin, I would like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance.

Ryan HayesInvestor Relations Analyst

They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance, and achievements to differ materially from those expressed or implied by the statement. Please see the forward-looking statement disclaimer on the company's press release issued earlier today, as well as the risk factors section in our Forms 10-Q and 10-K filed with the SEC. In addition, any forward-looking statements represent our views only as of the date such statements are made, November 2nd, 2026, and Travere specifically disclaims any obligation to update such statements to reflect future information, events, or circumstances. With that, let me now turn the call over to Eric.

Eric DubePresident and CEO

Good afternoon, and thank you for joining us today as we discuss another quarter of excellent execution and continued momentum across Travere's commercial business and pipeline. Before turning to our results, I'd like to briefly reflect on my upcoming transition that was announced during the quarter. As I prepare to step down in December, I've been reflecting on the people and purpose that have shaped my time at Travere. Being part of this company has been the greatest privilege of my career, and I am deeply proud of what we've accomplished. I have never been more confident that Travere's best days are ahead, with an exceptional executive team, life-changing therapies, and a growing pipeline, and an organization committed to delivering for patients. I've been in regular communication with Bradley as we plan for him joining Travere on December 1st.

Eric DubePresident and CEO

This time together has only strengthened my conviction that he is the perfect fit to lead Travere into its next chapter. He shares our commitment to patients and brings the experience, perspective, and leadership to build on our momentum. We are approaching this transition from a position of strength, and you'll hear that reflected in the progress we're sharing today. With that, let's turn to the advancements we've made for the quarter. The third quarter was marked by excellent execution across our business and continued progress against our four key pillars of our strategy to drive both near and long-term growth. As we enter the final months of the year and look ahead to 2027, I am very pleased with the momentum we have built and the increasingly durable growth profile of our company.

Eric DubePresident and CEO

At the center of this momentum is FILSPARI, where strong patient demand, growing conversion, and consistent commercial execution supported significant revenue growth across IgA nephropathy and FSGS. Quarterly net product sales surpassed $200 million for the first time, marking an important milestone as we continue to reach more patients. In IgA nephropathy, FILSPARI continues to demonstrate its foundational role, with strong demand, steady conversion to paid prescriptions, and consistently high patient adherence despite new market entrants. Importantly, we are not simply adding new patients each quarter. We are building on a growing base of patients who remain on therapy over time. This dynamic is a powerful driver of recurring revenue and reinforces our confidence in FILSPARI's long-term growth potential. In FSGS, we remain encouraged by the early launch performance, with high adoption trends consistent with our expectations.

Eric DubePresident and CEO

We're still at the beginning of this opportunity and see substantial potential to reach more eligible patients as nephrologists gain experience with FILSPARI, and Peter will provide additional details shortly. This continued commercial momentum reinforces our confidence in achieving or exceeding more than $3 billion in annual FILSPARI sales by 2033. We've also made important progress strengthening FILSPARI's U.S. patent portfolio, including a recently issued patent directed at certain methods of use in IgA nephropathy and a notice of allowance for a patent application directed to certain methods of use in FSGS. The IgAN patent, and upon issuance, the FSGS patent, carry terms extending into 2037. Taken together, this commercial momentum and progress in our patent portfolio reinforce our belief in FILSPARI's potential to reach more patients and continue growing beyond 2033. An important part of that long-term opportunity is reaching more patients earlier in their disease journey.

Eric DubePresident and CEO

We are also encouraged that earlier diagnosis and treatment of IgA nephropathy and FSGS are being recognized within the federal government through the recently published landmark HHS Kidney Care National Plan. For these rare kidney diseases, timely diagnosis can help physicians and patients consider appropriate treatment options earlier in the patient journey, reflecting more proactive kidney care. These developments reinforce our broader ambition to build a leading rare disease company with multiple opportunities for the long term. Beyond FILSPARI, we are making tangible progress advancing the next growth opportunities for Travere. With the potential to become the first disease-modifying therapy for classical HCU, pegtibatinase represents an important opportunity to improve the lives of the estimated 7,000 to 10,000 people in the U.S. living with this devastating disease. Jula will share more on the progress of this important program shortly. We're also advancing our newest pipeline asset, civorebrutinib.

Eric DubePresident and CEO

During the quarter, our licensing and collaboration agreement with Everest became effective, and our teams are making progress. Its potential differentiated profile and opportunity across multiple immune-mediated kidney diseases, representing more than 130,000 prevalent patients, adds another compelling dimension to our long-term growth strategy. As I look at Travere today, I see a company with a proven ability to execute, a growing and increasingly durable commercial franchise, and a pipeline with multiple opportunities to deliver meaningful innovation. We have built the capabilities, relationships, and expertise to lead in rare kidney disease, and we are only beginning to realize the opportunity ahead. With that, I'll turn the call over to Peter for an update on our commercial performance.

Peter HeermaChief Commercial Officer

Peter? Sorry about that. Thank you, Eric.

Peter HeermaChief Commercial Officer

In the third quarter, we received 1,932 new patient start forms across IgA nephropathy and FSGS, reflecting continued strong and steady demand during a period when we typically see summer seasonality. We are pleased with this performance and the underlying dynamics of our business. We also continue to see strong conversion of new prescriptions to paid therapy and high patient adherence, allowing us to add meaningful numbers of new patients to an already substantial and growing base of patients on FILSPARI. The combination of our expected new patient demand, strong conversion, and patient persistence, now across two indications, puts us well on track to achieve or exceed $3 billion in FILSPARI sales by 2033. Let me start with providing some clinical color on IgA nephropathy.

Peter HeermaChief Commercial Officer

FILSPARI remains the most prescribed medicine approved for IgA nephropathy, reflecting its differentiated profile and foundational role in treatment. As additional therapies become available and this market evolves, physicians are increasingly considering how to sequence and combine treatment options. We believe FILSPARI is well-positioned to remain an important part of these evolving treatment strategies. We continue to see new patient start forms coming from repeat prescribers as well as new physician activation. The vast majority of FILSPARI prescriptions are for patients that have no prior experience with branded therapies, and market research indicate that FILSPARI is considered appropriate for more patients than any other branded IgAN medicine. This reflects the confidence that physicians have in FILSPARI's differentiated profile and how it is broadly applicable for their IgAN patients.

Peter HeermaChief Commercial Officer

Within the dynamic and rapidly evolving treatment paradigm, we believe FILSPARI is well-established as kidney-targeted treatment, replacing RAS inhibitors, consistent with the KDIGO guidelines. As new immune-directed therapies replace historical options, we expect these to address the immune-mediated processes upstream in the disease manifestation, while FILSPARI continues to provide kidney protection superior to maximally tolerated RAS inhibition. We believe these approaches will continue to be complementary for patients requiring proteinuria reduction and slowing disease progression. Our conversations with physicians, most recently at the ASN Kidney Week, reinforced their view of FILSPARI as a preferred kidney-targeted medicine and a strong foundation for combination therapy, a pattern we are beginning to see in prescribing practice. We left ASN with even greater confidence in this positioning, and Jula will discuss the supporting clinical evidence shortly. We also see a particular opportunity among patients with proteinuria below 1.5 gram per gram.

Peter HeermaChief Commercial Officer

This segment represents approximately 70% of the IgAN population, and FILSPARI is well-positioned to continue to penetrate this segment. This is also where we expect to see increasing biopsies, resulting in earlier diagnosis and a growing number of patients that can benefit from FILSPARI. As the IgAN market is continuing to expand and as more companies increase their commercial activities, nephrologists are evaluating how to sequence and combine therapies amidst greater demands on their time and attention. We expect these dynamics to contribute in quarter-over-quarter variability in new IgA nephropathy patient starts, but we see an enduring fundamental role for FILSPARI, which reinforces our confidence in a substantial long-term opportunity in this patient population. Turning to FSGS, we remain encouraged by the performance of the launch as we saw further strong demand during the third quarter. Our prescriber base expanded, and nephrologists began treating additional patients within their practices.

Peter HeermaChief Commercial Officer

Approximately 40% of the first-time FSGS prescribers during the quarter were new to FILSPARI, expanding the brand's reach and creating additional opportunities in IgA nephropathy as well. We also see substantial opportunity to deepen prescribing within practices. Approximately two-thirds of the nephrologists who have prescribed FILSPARI for FSGS have treated just one FSGS patient since launch. FILSPARI's potential use spans eligible adults and children aged 8 and older without nephrotic syndrome, including patients with primary, secondary, genetic, and unknown cause FSGS. Early prescribing has focused on patients with higher proteinuria across the segments, and as nephrologists gain experience, we expect broader use within practices, including among eligible patients with lower proteinuria, similar to the evolution we have seen in IgA nephropathy. Our conviction is reinforced by what we hear from nephrologists about the important and broad role that FILSPARI should play in the treatment of FSGS.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day